Safety Study of SGN-CD70A in Cancer Patients
Completed · Phase 1
Conditions studied: Renal Cell Carcinoma, Mantle-Cell Lymphoma, Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3
In brief
This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.
Key facts
- Study ID
- NCT02216890
- Run by
- Seagen Inc.
- People needed
- 38
- Starts
- 2014-08-01
- Expected to finish
- 2017-02-15
- Last updated by the study team
- 2018-04-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma
- Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies
- Confirmed positive CD70 expression on tumor tissue
- Eastern Cooperative Oncology Group performance status 0 or 1
- Adequate baseline hematologic, pulmonary, renal, and hepatic function
- Measurable disease
You may not qualify if…
- Prior treatment with anti-CD70 directed therapy unless CD70 expression is confirmed on tumor tissue obtained after the treatment
- Patients <100 days since prior allogeneic stem cell transplant
- Less than 4 weeks since prior treatment; or 2 weeks if patient experienced disease progression on the prior treatment
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- City of Hope National Medical Center — Duarte, California, United States
- Cardinal Bernardin Cancer Center / Loyola University Medical Center — Maywood, Illinois, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- Karmanos Cancer Institute / Wayne State University — Detroit, Michigan, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- James P. Wilmot Cancer Center / University of Rochester Medical Center — Rochester, New York, United States
- UNC Lineberger Comprehensive Cancer Center / University of North Carolina — Chapel Hill, North Carolina, United States
- University of Cincinnati Cancer Institute — Cincinnati, Ohio, United States
- Case Western Reserve University / University Hospitals Case Medical Center — Cleveland, Ohio, United States
- University of Pennsylvania / Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania, United States
- Medical University of South Carolina/Hollings Cancer Center — Charleston, South Carolina, United States
- Texas Oncology - Austin Midtown — Austin, Texas, United States
- Methodist Cancer Center — Houston, Texas, United States
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
- Seattle Cancer Care Alliance / University of Washington — Seattle, Washington, United States
- Northwest Cancer Specialists, P.C. — Vancouver, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.